DataString Consulting Company Logo
DataString Consulting Company Logo
Iomeprol Market
Home»Recent Reports»Iomeprol Market

Iomeprol Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1806046, Published - April 2025

Segmented in Administration (Intravenous, Intra-arterial, Intrathecal), Imaging Modality (Computed Tomography, Angiography, Urography, Venography & Arteriography, Other Radiographic Procedures), Product Strength, End User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Iomeprol Market Outlook

The market, for Iomeprol was estimated at $257.6 million in 2024; and it is anticipated to increase to $367.5 million by 2030 with projections indicating a growth to around $494.1 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.1% over the forecast period. The continual growth of the Iomeprol market is underpinned by several key factors. Chief among these is the persistent demand for improved contrast agents in medical imaging, coupled with an increasing prevalence of chronic and lifestyle-oriented diseases, which necessitate frequent radiographic examinations. Contributing to this upward trajectory is the emergence of more advanced imaging technologies, which, in turn, amplify the necessity for Iomeprol. Furthermore, the active engagement of pharmaceutical companies in research and development activities to enhance the efficiency of contrast agents bodes well for the sustained relevance and promising prospects of this market.


Iomeprol, a nonionic monomer contrast medium, is renowned for its low osmolality and high stability, which translates to minimal side effects and reactions. Predominantly utilized in angiographic procedures and computed tomography (CT) scans, it allows for superior visualization of blood vessels and internal body structures. The substances use in myelography and urography procedures is also noteworthy.


Market Size Forecast & Key Insights

2019
$257M2024
2029
$465M2034

Absolute Growth Opportunity = $208M

The Iomeprol market is projected to grow from $257.6 million in 2024 to $465 million in 2034. This represents a CAGR of 6.1%, reflecting rising demand across Diagnostic Imaging, Urologic Examinations and Vascular Interventions.

The Iomeprol market is set to add $208 million between 2024 and 2034, with manufacturer targeting Angiography & Urography Imaging Modality projected to gain a larger market share.

With Rising demand in diagnostic procedures, and Innovation in contrast media, Iomeprol market to expand 81% between 2024 and 2034.

Opportunities in the Iomeprol Market

Strategic Collaborations

Strategic collaborations with hospitals and healthcare institutes can offer a vast for Iomeprol. By partnering with such institutions, Iomeprol can solidify its presence in the market, thereby enhancing distribution and boosting overall sales.

Technological Innovations and Emerging Markets

The advent of innovative technologies in the field of radiology presents a significant for the growth of Iomeprol. As contrast agents become more essential in imaging procedures, the use of Iomeprol, a nonionic iodinated contrast medium, is set to increase due to its favorable safety profile, and reliable imaging results.

Emerging economies such as India, Brazil, and China are witnessing a surge in healthcare infrastructure. This surge combined with the increasing prevalence of diseases requiring imaging diagnosis opens up a new consumer base for Iomeprol.

Growth Opportunities in North America and Europe

Europe Outlook

While Europe stands as the second largest market for Iomeprol, its growth can be attributed to the strong prevalence of public health programs and sustained government funding. From a market perspective, the escalating demand for non-invasive diagnostic techniques and therapeutics paired with the rise in cardiovascular ailments and disorders significantly propels the growth opportunities of Iomeprol within the region. Despite this upward trajectory, Europe faces stringent regulatory procedures that pose challenges for product approval. However, the robust presence of key market players and continual product innovations have kept the competition healthy and dynamic. The continents drive to maintain high-quality healthcare standards alongside a growing geriatric population further underlines its market potential for Iomeprol.

North America Outlook

As a leading region in the global healthcare market, North America presents significant opportunities for Iomeprol, a commonly used contrast agent in imaging procedures. The dominant presence of pharmaceutical enterprises and advanced healthcare infrastructure in this region significantly drives the demand for Iomeprol. Furthermore, the regions focus on technological advancements in diagnostic procedures, the increasing prevalence of chronic diseases, and the aging population are other crucial drivers within the sector. However, the market is also characterized by intense competition, with several global players vying for a substantial market share, mitigating risks associated with price wars and patent expiry.

North America Outlook

As a leading region in the global healthcare market, North America presents significant opportunities for Iomeprol, a commonly used contrast agent in imaging procedures. The dominant presence of pharmaceutical enterprises and advanced healthcare infrastructure in this region significantly drives the demand for Iomeprol. Furthermore, the regions focus on technological advancements in diagnostic procedures, the increasing prevalence of chronic diseases, and the aging population are other crucial drivers within the sector. However, the market is also characterized by intense competition, with several global players vying for a substantial market share, mitigating risks associated with price wars and patent expiry.

Europe Outlook

While Europe stands as the second largest market for Iomeprol, its growth can be attributed to the strong prevalence of public health programs and sustained government funding. From a market perspective, the escalating demand for non-invasive diagnostic techniques and therapeutics paired with the rise in cardiovascular ailments and disorders significantly propels the growth opportunities of Iomeprol within the region. Despite this upward trajectory, Europe faces stringent regulatory procedures that pose challenges for product approval. However, the robust presence of key market players and continual product innovations have kept the competition healthy and dynamic. The continents drive to maintain high-quality healthcare standards alongside a growing geriatric population further underlines its market potential for Iomeprol.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, Japan, China, India are expected to grow at 4.0% to 5.9% CAGR

2

Emerging Markets : Indonesia, Brazil, South Africa are expected to grow at 7.0% to 8.4% CAGR

Market Analysis Chart

Several factors function as market drivers for Iomeprol. The prominent ones include the growing prevalence of diseases that necessitate the use of contrast agents in diagnostics, the expansion of technologically advanced imaging modalities, and the rise in research and development initiatives in the healthcare sector. Iomeprol, as a radiographic contrast medium, holds a significant market share, benefitting from these industry trends.

Recent Developments and Technological Advancement

December 2024

Pharmaceutical giant Bracco SpA announced a breakthrough innovation in the formulation of Iomeprol, resulting in improved patient tolerance and significantly reduced side effects.

October 2024

The FDA expanded the approved use of Iomeprol for diagnostic imaging in pediatrics, creating opportunities for the product in a new patient segment. This approval came after rigorous clinical trials by Bayer AG on the safety and effectiveness of Iomeprol in young patients.

July 2024

GE Healthcare unveiled their advanced processing methods for Iomeprol, which reduced its manufacturing cost and time, enhancing its market viability and affordability.

Iomeprol, an advanced iodinated contrast medium, has made substantial progress in the medical imaging market in recent times. This non-ionic contrast agent, employed in procedures like angiography and computed tomography, has been recognized for its distinguished radiographic performance. Significantly, Iomeprols market share has witnessed a sizable increase under the ongoing digital transformation within the healthcare sector.

Impact of Industry Transitions on the Iomeprol Market

As a core segment of the Other Healthcare industry, the Iomeprol market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Digital Technology and Focus on Ecofriendly Manufacturing have redefined priorities across the Other Healthcare sector, influencing how the Iomeprol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence of Digital Technology:

The adoption of digital technology has had a profound impact on the Iomeprol industry. Modern technologies are revolutionizing the ways medical practitioners access contrast agents like Iomeprol for diagnostic procedures. Digitization, IOT , and AI platforms are facilitating realtime monitoring of supply chain processes, leading to streamlined operations and reduced waste. This digital transition has not only resulted in improved operational efficiency, but is also setting a new standard in the healthcare industry, encouraging other sectors to follow suit.

2

Focus on Ecofriendly Manufacturing:

Pressure from governmental bodies and environmental groups has led to a shift in the production methods of Iomeprol towards greener, more sustainable methods. Recent strides in chemical synthesis have allowed for the creation of this radiocontrast agent using procedures with reduced byproducts and minimal environmental impact. This shift towards ecofriendly manufacturing is starting to reshape theindustry'simpact on the environment and has set a precedent for other pharmaceutical products to follow similar sustainable approaches in production.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Other Healthcare industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Other Healthcare industry cascade into the Iomeprol market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Demand in Diagnostic Procedures, and Emergence of Tailored Formulations

The widespread use of Iomeprol in medical imaging particularly in X-rays and CT scans underlies its increasing demand. Given the escalating prevalence of diseases requiring diagnostic procedures, Iomeprol use as a contrast agent is also anticipated to grow exponentially.
The introduction of tailored formulations of Iomeprol for specific applications is also an emerging trend. This can also be seen in the varied concentrations of Iomeprol developed for differents of medical imaging procedures. It bodes well for the market growth as it caters to the precise needs of healthcare professionals and patients.
The market for Iomeprol is also spurred by continuous technological advancements in contrast media. Iomeprol, with its excellent tolerability and lower risk of kidney damage, leads the curve in non-ionic contrast media, which is also a growth sector within the industry.

Restraint: High Costs of Production

The manufacturing process of Iomeprol, a non-ionic, iso-osmolar contrast agent, often involves complex synthesis techniques and stringent quality control, resulting in a significant increase in production expenses. These high costs, in turn, impact the price point of the final product, potentially deterring price-sensitive buyers, thereby restraining market growth.

Challenge: Regulatory Hurdles

Governments across the globe have put stringent guidelines in place for pharmaceuticals like Iomeprol. While these regulations are essentially intended to ensure the safety and efficacy of such products, the process of obtaining necessary approvals can be both time-consuming and costly, acting as a significant barrier for new entrants as well as existing market players. These regulatory hurdles can delay the launch of products, directly affecting the market dynamics, and serve as a major obstacle to the growth of the Iomeprol market.

Supply Chain Landscape

Raw Material Procurement

BASF SE

Dow Chemical Company

Drug Synthesis

Sanofi S.A.

AstraZeneca

Formulation & Packaging
Bayer AG / Merck KGaA
Market Distribution
Novartis AG / Pfizer Inc
Raw Material Procurement

BASF SE

Dow Chemical Company

Drug Synthesis

Sanofi S.A.

AstraZeneca

Formulation & Packaging

Bayer AG

Merck KGaA

Market Distribution

Novartis AG

Pfizer Inc

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Diagnostic Imaging
Healthcare
Bracco S.p.A
Development of optimum injection solutions for best imaging results
Vascular Contrast Medium
Healthcare
Bayer AG
Continuous innovation in radiology and diverse portfolio to optimize patient experience
Nephrographic Phases
Healthcare
GE Healthcare
Development of tailored agents to provide efficient results in nephrographic imaging
Central Nervous System Procedures
Healthcare
Guerbet
Manufacturing highly targeted agents to reduce risks and enhance image clarity

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Iomeprol market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Iomeprol in Urologic Examinations, Vascular Interventions and Diagnostic Imaging

Urologic Examinations

Lastly, Iomeprol is an essential component in urologic examinations, increasing the contrast in urinary structures to assist in diagnosing renal conditions. This application has attracted market leaders who resort to leveraging the high-quality imaging capbilities of Iomeprol to achieve diagnostic precision, thereby elevating their market presence.

Vascular Interventions

Iomeprol also sees prominent use in vascular interventions. Its role here is to enhance the visualization of blood vessels during endovascular procedures, playing a critical role in interventional cardiology and radiology. Leading companies in this sector have a marked competitive advantage, thanks to their dedicated focus on patient safety, alongside the strategic use of Iomeprol.

Diagnostic Imaging

Iomeprol is principally used in diagnostic imaging as an X-ray contrast agent. It enhances the visibility of certain internal structures during radiographic procedures, aiding clinicians in making precise diagnoses. Top players leveraging Iomeprol in this domain include renowned pharmaceutical corporations boasting a strong market position due to both their innovative imaging technologies and proven safety record.

Iomeprol vs. Substitutes:
Performance and Positioning Analysis

Iomeprol distinguishes itself from alternatives like Iodixanol and Iopamidol due to its superior tolerability and efficient imaging results. Market projections indicate strong potential growth backed by its unique positioning in the radiographic contrast media sector

Iomeprol
  • Iopamidol /
  • Iodixanol /
  • Iohexol
    Excellent contrast enhancement, low incidence of side effects
    Potential renal toxicity, relatively high cost
    High contrast quality, Lower risk of side effects
    Higher cost, Unavailability in certain markets

Iomeprol vs. Substitutes:
Performance and Positioning Analysis

Iomeprol

  • Excellent contrast enhancement, low incidence of side effects
  • Potential renal toxicity, relatively high cost

Iopamidol / Iodixanol / Iohexol

  • High contrast quality, Lower risk of side effects
  • Higher cost, Unavailability in certain markets

Iomeprol distinguishes itself from alternatives like Iodixanol and Iopamidol due to its superior tolerability and efficient imaging results. Market projections indicate strong potential growth backed by its unique positioning in the radiographic contrast media sector

Loading...

Research Methodology

This market research methodology defines the Iomeprol market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Other Healthcare ecosystem, we analyze Iomeprol across Hospitals, Diagnostic Imaging Centers, and Specialty Clinics Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Bracco S.p.A., Guerbet Group, and GE Healthcare by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Drug Synthesis, and Formulation & Packaging. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Other Healthcare revenues to estimate the Iomeprol segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (BASF SE, Dow Chemical Company), Drug Synthesis (Sanofi S.A., AstraZeneca), and Formulation & Packaging. Our parallel substitute analysis examines Iopamidol, Iodixanol, and Iohexol, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Bracco S.p.A., Guerbet Group, and GE Healthcare, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Iomeprol market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Iomeprol Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 273 million
Revenue Forecast in 2034USD 465 million
Growth RateCAGR of 6.1% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024257 million
Growth OpportunityUSD 208 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024257 million USD
Market Size 2027307 million USD
Market Size 2029346 million USD
Market Size 2030367 million USD
Market Size 2034465 million USD
Market Size 2035494 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredAdministration, Imaging Modality, Product Strength, End User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledBracco S.p.A., Guerbet Group, GE Healthcare, Bayer AG, Jiangsu Hengrui Medicine, Aurobindo Pharma, J.B. Chemicals and Pharmaceuticals, Alembic Pharmaceuticals, Sanofi S.A., Cadila Healthcare, MPI Research and Shanghai Pharmaceuticals
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Iomeprol Market Size, Opportunities & Strategic Insights, by Administration

4.1Intravenous
4.2Intra-arterial
4.3Intrathecal
Chapter 5

Iomeprol Market Size, Opportunities & Strategic Insights, by Imaging Modality

5.1Computed Tomography
5.2Angiography
5.3Urography
5.4Venography & Arteriography
5.5Other Radiographic Procedures
Chapter 6

Iomeprol Market Size, Opportunities & Strategic Insights, by Product Strength

6.1300 mg Iodine/mL
6.2350 mg Iodine/mL
6.3400 mg Iodine/mL
Chapter 7

Iomeprol Market Size, Opportunities & Strategic Insights, by End User

7.1Hospitals
7.2Diagnostic Imaging Centers
7.3Specialty Clinics
Chapter 8

Iomeprol Market, by Region

8.1North America Iomeprol Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Iomeprol Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Iomeprol Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Iomeprol Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Iomeprol Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Iomeprol Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Bracco S.p.A.
9.2.2Guerbet Group
9.2.3GE Healthcare
9.2.4Bayer AG
9.2.5Jiangsu Hengrui Medicine
9.2.6Aurobindo Pharma
9.2.7J.B. Chemicals and Pharmaceuticals
9.2.8Alembic Pharmaceuticals
9.2.9Sanofi S.A.
9.2.10Cadila Healthcare
9.2.11MPI Research
9.2.12Shanghai Pharmaceuticals